India's infants to receive Shantha Biotechnics' 'Made in India' ShanIPV™ for polio eradication

- Shantha Biotechnics is the first Indian company to supply IPV via UNICEF to the Indian Government -

- Recent introduction of IPV in India's UIP is in keeping with Global Polio Endgame Strategy -

Mumbai, December 4th, 2015: Further to India's introduction of IPV in Universal Immunisation Programme (UIP), Sanofi Pasteur, the vaccines division of Sanofi, announced today the launch of ShanIPV™, an injectable inactivated polio vaccine (IPV) by **Shri K. Chandrasekhar Rao, Hon'ble Chief Minister of Telangana**. ShanIPV™ will be 'made in India' by Sanofi Pasteur's affiliate Shantha Biotechnics Private Limited in Hyderabad. ShanIPV™ is a trivalent inactivated, injectable polio vaccine.

Declared as a polio-free nation in 2014, heralding a great victory over the disease, India's current war will be waged against its reemergence. This is where ShanIPV™, manufactured through technology transfer from Sanofi Pasteur, will make its contribution. India is now poised to progress to the next and final step of polio eradication, the final elimination of all vaccine-related and vaccine-derived polio viruses. This step will secure the future of millions of children in India.

Dr. Shailesh Ayyangar, Managing Director - India and Vice President - South Asia, Sanofi commenting on the launch said, "*Today, we are proud to further strengthen our commitment towards disease prevention and support the Indian Government's Universal Immunisation Programme - including polio eradication. With the introduction of IPV in the immunisation schedule, our Company is playing a key role in achieving the goal of a polio-free world.*"

Only two countries in the world are still classified as polio endemic, meaning that wild polio virus passes routinely between members of the community. However, great progress has been made in both countries and the last case of polio in the world may possibly be only months away. India has had a very strong focus on polio eradication and this move to introduce IPV in the UIP will provide the required impetus for a polio free India.

***Jean-Pierre Baylet, Country Head – Vaccines, Sanofi Pasteur, India said**, "Sanofi Pasteur has been a public health partner to India for over 20 years. We welcome the Government of India's decision to introduce IPV in the immunisation program to eliminate the risk of polio virus resurgence. This is a big milestone in the Country towards ensuring a future when no child succumbs to this vaccine-preventable disease. We are very pleased that Sanofi Pasteur and Shantha Biotechnics supply vital technological know-how and are key partners to the Government of India, WHO and UNICEF for polio eradication in the Country."*

In line with the WHO's Global endgame strategy, India is introducing one dose of IPV at 14 weeks of age. IPV is to be given in addition to the existing oral polio vaccine. This introduction is a critical step

towards achieving a polio-free world by 2019 to meet the Global Polio Eradication Initiative (GPEI) Endgame Strategic Plan.

Dr. Mahesh Bhalgat, Executive Director & Chief Operating Officer, Shantha Biotechnics, India said, *"At Shantha, our goal is to deliver healthcare solutions, which can be accessed by the common man in India. Towards the polio eradication programme, we will manufacture massive quantities of high-quality, safe and efficacious IPV vaccine to meet all the milestones in the timeline set by the Indian Government."*

ShanIPV™ is currently approved for use in the Indian market and will be distributed in India. The primary focus is to supply doses to Indian population.

About ShanIPV™

ShanIPV™ is a trivalent inactivated, injectable polio vaccine. The first manufacturing steps (trivalent bulk preparation) are carried out in Sanofi Pasteur's Marcy l'Etoile site in France. The final steps (formulation, filling and packaging) are performed by Shantha in their facilities in Hyderabad, India. ShanIPV™ is currently approved for use in the Indian market and will be distributed in India.

About Shantha

Shantha, which was acquired by Sanofi Pasteur Holding in 2009, is a biotechnology pioneer from the emerging countries, founded by Dr. K I Varaprasad Reddy in 1993 in Hyderabad, India. Shantha is a fully integrated biotechnology company involved in R&D, manufacturing and marketing. Shantha's mission is to develop, produce and market healthcare products, which are affordable and meet the highest International standards. Shantha's products complement Sanofi Pasteur's portfolio. Four of its licensed vaccines are WHO-prequalified: Shan5™ pediatric vaccine, Shanchol™ cholera vaccine, Shanvac-B® hepatitis B vaccine, and ShanTT™ tetanus vaccine. Sanofi Pasteur and Shantha are also developing a new pediatric combination vaccine based on Shan5 that will incorporate Sanofi Pasteur's Inactivated Polio Vaccine (IPV) in order to secure polio eradication.

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunise more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers a broad range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests

more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Global Media Relations
Alain Bernal
T. +33-4-37-37-50-38
alain.bernal@sanofipasteur.com
www.sanofipasteur.com

India Media Relations

Sanofi
Aparna Thomas
T. +91-22-28-27-81-69
aparna.thomas@sanofi.com
www.sanofi.com

Shantha
Tashif Ayaz
T. +91-40 – 66-30-11-04
tashif.ayaz@sanofi.com
www.shanthabiotech.com